文献速递胸部肿瘤乳腺癌消化系统肿瘤

ERBB3突变癌症中HER家族抑制剂的应用探索

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
PubMed 文献 · Eur J Cancer · 2018-02-03

本研究从分子筛查项目中筛选携带ERBB3体细胞突变的患者,评估HER家族抑制剂在ERBB3突变癌症中的临床效用。844例患者中31例(3.7%)存在ERBB3突变,其中9例接受HER家族抑制剂治疗;4例酪氨酸激酶结构域突变患者接受含拉帕替尼或阿法替尼的治疗后,无进展生存和总生存均显著改善。

要点

  • 844例分子筛查患者中ERBB3突变率为3.7%(31例)。
  • 4例HER3酪氨酸激酶结构域突变者接受含拉帕替尼或阿法替尼治疗,PFS和OS显著获益。

核心结论

  • 探索性分析提示HER3蛋白酪氨酸激酶结构域突变与HER家族抑制剂治疗下的良好预后相关。

研究设计与样本

  • 研究纳入机构分子筛查项目中检出ERBB3体细胞变异的患者,筛查技术为靶向二代测序、比较基因组杂交和/或全外显子测序,标本为新鲜冷冻肿瘤活检。
  • 844例患者具有肿瘤分子图谱,其中31例(3.7%)携带ERBB3体细胞突变。

主要发现

  • 4例肿瘤检出HER3酪氨酸激酶结构域突变,单变量分析中与良好无进展生存(HR=0.18,p=0.022)和总生存(HR=0.19,p=0.03)显著相关。
  • 上述4例患者的治疗至少包含酪氨酸激酶抑制剂拉帕替尼或阿法替尼。

临床怎么用

  • 对ERBB3突变患者可考虑检测突变是否位于酪氨酸激酶结构域,该部位突变者或可从含拉帕替尼或阿法替尼的HER家族抑制剂治疗中获益。

局限性

  • 本研究为探索性分析,样本量小,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Therapeutic inhibition of the human epidermal receptor 3 (ERBB3, HER3) has been challenged by the low frequency of ERBB3 somatic alterations across cancer types. We have evaluated the clinical utility to use available inhibitors of the HER family in the context of ERBB3 mutations. PATIENTS AND METHODS: In this study, we have selected patients with somatic ERBB3 alterations detected in their tumours from the molecular screening programs running at our institution. Techniques used for molecular screening were targeted next generation sequencing, comparative genomic hybridisation and/or whole exome sequencing on fresh frozen tumour biopsies. RESULTS: On the 844 patients with a molecular portrait of their tumours, 31 (3.7%) had a somatic mutation of ERBB3. Overall, 9 patients received available inhibitors of HER family, including trastuzumab and/or lapatinib or afatinib. Sixteen patients received other molecularly targeted agents, including the Mammalian Target Of Rapamycin (mTOR), the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase (PI3K) or NOTCH inhibitors or chemotherapy, and 4 patients failed being treated. Thirteen different histological subtypes were affected by ERBB3 mutations; top ones were colorectal carcinomas (6 patients), non-small cell lung cancers (4 patients, including a squamous cell carcinoma), head and neck squamous cell carcinomas (3 patients) and breast carcinomas (3 patients). The presence of a mutation in the tyrosine kinase domain of the ERBB3/HER3 protein detected in four patients' tumours was significantly related to good progression-free survival (hazard ratio [HR] = 0.18, p value = 0.022) and overall survival (HR = 0.19, p value = 0.03) in univariate analysis. Treatment of these four patients included at least a tyrosine kinase inhibitor lapatinib or afatinib. CONCLUSION: Our exploratory analysis suggests that mutations in the tyrosine kinase domain of the HER3 protein are related to a favourable outcome under HER family inhibitors.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Verlingue L, Hollebecque A, Lacroix L, et al. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. Eur J Cancer. 2018. PMID: 29413684. doi:10.1016/j.ejca.2017.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。